<DOC>
	<DOCNO>NCT01293747</DOCNO>
	<brief_summary>Phase I pharmacokinetic study Main objective : To determine plasmatic profile pharmacokinetic parameter estradiol progesterone formulation study , multiple-dose administration Study design : Randomized , control , open-label , parallel , pharmacokinetic study Sites : 1 Subjects : 30 postmenopausal woman</brief_summary>
	<brief_title>Pharmacokinetics Injectable Estradiol Progesterone Microspheres Suspension</brief_title>
	<detailed_description>Sites : 1 Phase : 1 Main objective : To determine plasmatic profile pharmacokinetic parameter estradiol progesterone formulation study , multiple-dose administration . Secondary objective : To determine bioavailability formulation study , multiple-dose-administration . Describe tolerability formulation study , multiple-dose administration . Study design : Randomized , control , open-label , parallel , pharmacokinetic study Investigational Products : - Estradiol progesterone microspheres aqueous suspension ( 1 mg/20 mg ) - Estradiol progesterone microspheres aqueous suspension ( 0.5 mg/15 mg ) Study subject : 30 postmenopausal woman 45 - 65 year old Brief description : After write informed consent , 30 eligible woman randomize study treatment ( one IM injection 28 day , total 4 dos ) . Blood sample obtain pharmacokinetic study .</detailed_description>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Female 45 65 year old Able read write Postmenopausal Body Mass Index equal 34.99 kg/m2 Healthy Normal uterus Time availability Hypersensitivity progesterone relate compound Hypersensitivity estrogens Hysterectomy History present hormonedependent tumor History present uterine cervix dysplasia Abnormal clinicallysignificant laboratory test result Family history breast cancer History thromboembolic disease Noncontrolled hypertension History stroke History cardiac valve surgery Renal failure Hepatic failure Noncontrolled diabetes History serious neurologic disease Reduced mobility Anemia Previous concomitant hormone therapy Previous concomitant therapy inhibitor inductor cytochrome</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Estrogen</keyword>
	<keyword>Progesterone</keyword>
	<keyword>Microspheres</keyword>
	<keyword>Menopause</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>